Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis

BACKGROUND: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Goulart, Bernardo HL, Clark, Jeffrey W, Lauwers, Gregory Y, Ryan, David P, Grenon, Nina, Muzikansky, Alona, Zhu, Andrew X
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2663565/
https://ncbi.nlm.nih.gov/pubmed/19291303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados